Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


1234>>>
84 Items
Title  Creator  Group name  Publishing year 
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2023-02-02
Robustness of Breast Margins with Volumetric Modulated Arc Therapy without a Six-Degrees-of-Freedom Couch: A Dosimetric Evaluation Prunaretty et al. EquipeJPP 2023-01-21
Implementation of the Calypso system: a commissioning experience Prunaretty et al. EquipeJPP 2023
Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer Jandu et al. EquipeJPP 2023-10
Contouring variation affects estimates of normal tissue complication probability for breast fibrosis after radiotherapy Jaikuna et al. EquipeJPP 2023-09-11
Comparison of prone and supine positioning for breast cancer radiotherapy using REQUITE data: dosimetry, acute and two years physician and patient-reported outcomes Vakaet et al. EquipeJPP 2023-09
Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study Heumann et al. EquipeJPP 2023-01
Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey Samaran et al. EquipeJPP 2023-07
A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors Bordeau et al. EquipeMY 2023-09-20
(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer Rosas et al. EquipeJPP 2023-11-01
[Non-pharmalogical interventions and breast cancer: What benefit in addition to radiotherapy?] Lognos et al. EquipeJPP 2022-06
[Formation of French oncology resident: A national survey] Rousseau et al. EquipeJPP 2022
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer Kerns et al. EquipeJPP 2022-03
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort Webb et al. EquipeJPP 2022-10
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study van der Weijst et al. EquipeJPP 2022-11
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study Michalet et al. EquipeMY 2022
Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results Michalet et al. EquipeJPP 2022-12-30
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2022-12-20
Spreading geriatric oncology culture through professional caregivers: Results of a French massive open online course (MOOC) Nicolas et al. EquipeJPP 2022-01
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study) Van der Weijst et al. EquipeJPP 2022-04
Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study Michalet et al. EquipeJPP 2022-04-12
Improving Patients' Life Quality after Radiotherapy Treatment by Predicting Late Toxicities Lapierre et al. EquipeJPP 2022-04-22
High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer Joseph et al. EquipeJPP 2022
Efficacy, safety, and feasibility of volumetric modulated arc therapy for synchronous bilateral breast cancer management Quesada et al. EquipeJPP 2022
Different meaning of the mean heart dose between 3D-CRT and IMRT for breast cancer radiotherapy Prunaretty et al. EquipeJPP 2022
1234>>>
84 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés